David A. Siegel Sangamo Therapeutics, Inc Transaction History
Two Sigma Advisers, LP
- $47 Billion
- Q3 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Sangamo Therapeutics, Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 2,108,355 shares of SGMO stock, worth $927,676. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,108,355
Previous 1,206,734
74.72%
Holding current value
$927,676
Previous $651,000
116.9%
% of portfolio
0.0%
Previous 0.0%
Shares
32 transactions
Others Institutions Holding SGMO
# of Institutions
124Shares Held
62.5MCall Options Held
953KPut Options Held
1.11M-
Vanguard Group Inc Valley Forge, PA11.6MShares$5.11 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny10.2MShares$4.48 Million0.01% of portfolio
-
Black Rock Inc. New York, NY4.7MShares$2.07 Million0.0% of portfolio
-
Gsa Capital Partners LLP London, X03.66MShares$1.61 Million0.21% of portfolio
-
Geode Capital Management, LLC Boston, MA3.29MShares$1.45 Million0.0% of portfolio
About SANGAMO THERAPEUTICS, INC
- Ticker SGMO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 156,552,992
- Market Cap $68.9M
- Description
- Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucle...